What Is Tirzepatide? How the Dual GLP-1/GIP Agonist Works

When the FDA approved tirzepatide for chronic weight management under the brand name Zepbound in late 2023, it marked a genuine turning point in obesity medicine. This wasn't just another incremental improvement — the clinical trial data showed weight loss results that exceeded anything seen with prior medications, including the already-impressive semaglutide.

Understanding what tirzepatide is, how it works, and who it's right for requires understanding a bit of pharmacology — specifically, the difference between single-receptor and dual-receptor agonism. This guide explains everything clearly.

What Is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — a novel class of medication developed by Eli Lilly. It is a single synthetic peptide molecule that simultaneously activates two distinct hormone receptors involved in blood sugar regulation and appetite control.

It is marketed under two brand names depending on its FDA-approved indication:

• Mounjaro: Approved for type 2 diabetes management (May 2022)
• Zepbound: Approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (November 2023)

Despite different brand names and different approvals, Mounjaro and Zepbound are the same drug at the same doses. The distinction matters primarily for insurance coverage purposes.

How Tirzepatide Differs from Semaglutide

To understand tirzepatide's advantage, it helps to start with semaglutide (Ozempic, Wegovy). Semaglutide is a GLP-1 receptor agonist only — it mimics the action of one hormone: GLP-1. By activating GLP-1 receptors in the brain, pancreas, and gut, semaglutide suppresses appetite, slows gastric emptying, and improves blood sugar regulation.

Tirzepatide does all of this — and more. It also activates GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that plays a distinct but complementary role to GLP-1. Activating both receptors simultaneously produces a synergistic effect that exceeds what either hormone can achieve alone.

Clinical Trial Results: SURMOUNT-1

The landmark clinical trial for tirzepatide's weight loss efficacy is SURMOUNT-1, published in the New England Journal of Medicine in 2022. This was a phase 3, randomized, double-blind, placebo-controlled trial enrolling 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Participants received tirzepatide at 5mg, 10mg, or 15mg weekly, or placebo, for 72 weeks — all alongside lifestyle intervention. The results were remarkable:

• 5mg dose: Average weight loss of 15% of body weight
• 10mg dose: Average weight loss of 19.5% of body weight
• 15mg dose: Average weight loss of 22.5% of body weight
• Placebo: 2.4% weight loss

At the 15mg dose, 57% of participants lost 20% or more of their body weight — a level of efficacy previously only achievable with bariatric surgery. Approximately 37% lost 25% or more of their body weight.

How Tirzepatide Works: The Dual Mechanism Explained

GLP-1 Receptor Activation

GLP-1 receptors are found in the hypothalamus (the brain's appetite control center), the gut, and the pancreas. When activated, GLP-1 signaling:

• Reduces appetite by signaling satiety to the hypothalamus
• Slows gastric emptying (food moves more slowly from stomach to intestine), extending feelings of fullness
• Stimulates glucose-dependent insulin secretion, lowering blood sugar after meals
• Reduces glucagon release, preventing excess glucose production by the liver

GIP Receptor Activation

GIP receptors are expressed in fat tissue, brain, bone, and pancreas. GIP receptor activation by tirzepatide appears to:

• Enhance the appetite-suppressing effects of GLP-1 signaling in the brain
• Improve insulin sensitivity in peripheral tissues (muscle, fat, liver)
• Reduce the nausea side effects typically associated with GLP-1 agonism at high doses — potentially allowing patients to tolerate higher effective doses
• Improve lipid metabolism and reduce fat cell size independently of weight loss

The synergy between these two mechanisms explains why tirzepatide produces substantially greater weight loss than semaglutide despite similar injection schedules and tolerability profiles.

Dosing: The Tirzepatide Titration Schedule

Tirzepatide is administered as a once-weekly subcutaneous injection. The titration schedule is designed to minimize gastrointestinal side effects during the dose escalation phase:

• 2.5mg/week — Weeks 1–4 (initiation dose, not a therapeutic dose)
• 5mg/week — Weeks 5–8
• 7.5mg/week — Weeks 9–12
• 10mg/week — Weeks 13–16
• 12.5mg/week — Weeks 17–20
• 15mg/week — Week 21+ (maximum maintenance dose)

Not all patients need to escalate to 15mg. Many achieve their weight loss goals at 10mg or 12.5mg, and physicians may pause escalation if a patient is experiencing significant side effects or has already reached their target. The goal is the lowest effective dose, not the highest dose possible.

Side Effects and How to Manage Them

Tirzepatide's side effect profile is similar to other GLP-1 medications, though many patients report better tolerability than semaglutide — potentially due to the GIP component counteracting some GLP-1-mediated nausea.

Most common side effects:

• Nausea (most common, especially during dose escalation)
• Diarrhea
• Constipation
• Vomiting
• Decreased appetite (often desired, but can reduce food intake too sharply)
• Injection site reactions (mild redness, bruising)

Management strategies:

• Eat smaller, more frequent meals — large meals significantly worsen nausea
• Avoid high-fat, greasy, or spicy foods, especially in the first weeks of a new dose
• Stay well-hydrated — diarrhea and vomiting can cause dehydration
• Don't lie down immediately after eating
• If nausea is severe, ask your physician about extending the time at each dose before escalating

Serious side effects (rare): Pancreatitis, gallbladder disease, hypoglycemia (primarily in diabetic patients), and thyroid C-cell concerns based on animal studies (tirzepatide carries a boxed warning for thyroid cancer risk in patients with a personal or family history of medullary thyroid carcinoma).

Who Is the Best Candidate for Tirzepatide?

Tirzepatide (Zepbound) is FDA-approved for adults who meet at least one of these criteria:

• BMI ≥30 kg/m² (obesity)
• BMI ≥27 kg/m² (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

In practice, the best candidates are patients who want maximum weight loss efficacy, who have tried semaglutide and plateaued, or who have type 2 diabetes alongside obesity (where tirzepatide's dual mechanism provides additional metabolic benefits). Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) should not use tirzepatide.

Zepbound vs. Mounjaro: Same Drug, Different Approvals

This is one of the most common points of confusion about tirzepatide. Zepbound and Mounjaro contain identical active ingredients at identical doses. The molecule is the same; the clinical indication on the FDA approval is different.

• Mounjaro — FDA-approved for glycemic control in adults with type 2 diabetes
• Zepbound — FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities

Physicians can also prescribe Mounjaro off-label for weight loss in non-diabetic patients, just as they prescribe Ozempic off-label for weight loss. Insurance coverage often differs: patients with type 2 diabetes may have Mounjaro covered for its diabetes indication, while Zepbound coverage for weight loss varies by plan. Compounded tirzepatide — when available from an FDA-registered 503B pharmacy — provides an affordable alternative when neither brand has insurance coverage.